To evaluate costs, benefits and cost-effectiveness of anti-TNF agents in PsA patients with inadequate response to conventional treatment.
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy / Olivieri, I; de Portu, S; Salvarani, Carlo; Cauli, A; Lubrano, E; Spadaro, A; Cantini, F; Cutro, M. S; Mathieu, A; Matucci Cerinic, M; Pappone, N; Punzi, L; Scarpa, R; Mantovani, L. G.. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 47:11(2008), pp. 1664-1670. [10.1093/rheumatology/ken320]
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
SALVARANI, CARLO;
2008
Abstract
To evaluate costs, benefits and cost-effectiveness of anti-TNF agents in PsA patients with inadequate response to conventional treatment.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
